465 related articles for article (PubMed ID: 10522021)
1. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
5. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
6. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
10. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
11. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
[TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
Sakizono K; Oita T; Shibata Y; Tamura A; Kasakura S
Rinsho Byori; 1998 Sep; 46(9):936-41. PubMed ID: 9800480
[TBL] [Abstract][Full Text] [Related]
14. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
16. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
17. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
[TBL] [Abstract][Full Text] [Related]
18. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma.
Tanabe Y; Ohnishi K; Nomura F; Iida S
Am J Gastroenterol; 1988 Dec; 83(12):1386-9. PubMed ID: 2461655
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
[TBL] [Abstract][Full Text] [Related]
20. [Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma].
Yoon YJ; Han KH; Kim C; Chon CY; Moon YM; Han CH; Choi HJ; Kim YS; Han JY; Kim HS
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):465-71. PubMed ID: 12506251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
